Abstract： OBJECTIVE To observe the effect of sacubitril valsartan on blood uric acid in patients with chronic heart failure com-bined with hyperuricemia,and to provide new ideas for the treatment of patients with chronic heart failure and hyperuricemia as well as drug selection.METHODS 108 inpatients with chronic heart failure combined with hyperuricemia diagnosed at the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital)from November 2021 to June 2022 were se-lected,and were divided into 41 cases of the control group using valsartan and 67 cases of the observation group using sakubatrizol valsartan according to the medication use of the patients,and the basic information and history of each patient as well as the current use of drugs were collected.The basic information and medical history of each patient as well as the current use of medication were collected,and the patients'blood uric acid before treatment was perfected,and valsartan or ARNI was used on the basis of receiv-ing the conventional treatment of heart failure and no other uric acid-lowering medication was used,respectively.The changes of blood uric acid in the third and sixth months after the treatment of the patients were observed in the followups.RESULTS At 3 months after treatment,there was no significant difference in blood uric acid level between control group and before treatment(P＞0.05).The serum uric acid level in observation group was significantly lower than before treatment,with statistical significance(t=10.061,(P＜0.05).There was statistical significance in the decrease of blood uric acid level between the two groups(t=5.681,P＜0.01).At 6 months after treatment,the serum uric acid level in 2 groups was significantly lower than before treatment,with statis-tical significance(t=3.195,P＜0.05).There was statistical significance in the decrease of blood uric acid level between the two groups(t=5.365,P＜0.01).CONCLUSION Sacubactrivalsartan can reduce the blood uric acid level in patients with chronic heart failure complicated with hyperuricemia,and can be given priority in clinical use in patients with chronic heart failure complicated with hyperuricemia to reduce the initiation of urico-lowering related therapy.